Objective: In humans, a single exposure to phencyclidine (PCP) can induce a schizophrenia-like psychosis which can persist for up to two weeks. In rats, an acute dose of PCP increases dopaminergic activity and causes changes in dopamine related behaviours some of which are sexually dimorphic. To better understand the effects of PCP on dopamine receptor adaptations in the short term we examined dopamine D1-like receptors (D1R) and D2-like receptors (D2R) in the mesolimbic and nigrostriatal dopamine pathways, 4 hours after exposure to PCP in female rats. Methods: Animals received a single dose of 40 mg/kg PCP and were sacrificed 4 hours later. In vitro autoradiography was carried out using [ 
INTRODUCTION
Phencyclidine (PCP) is an N-methyl-D-aspartate (NM-DA) receptor antagonist that was first developed as an anaesthetic but is now a widely abused street drug. 1, 2) It induces a schizophrenia-like syndrome in normal individuals and a single exposure to PCP can lead to psychosis in humans lasting up to two weeks. 3, 4) PCP has proved a valuable resource for modelling behaviours relevant to some symptoms of schizophrenia in laboratory animals. Understanding the neurochemical alterations underlying the behavioural changes that take place following PCP exposure may therefore have possible relevance to the pathophysiology associated with psychosis and schizophrenia.
In rodents, a single dose of PCP induces a range of dopamine related behaviours such as hyperlocomotion, cataleptic freeze, stereotyped behaviour and deficits in the sensory gating measure-prepulse inhibition. [5] [6] [7] [8] [9] [10] It also induces deficits in learning and memory in the rat, cat and rhesus monkey. 1, 11) In rats treated with various doses of PCP (19.5, 32.6 , 54.4 mg/kg), stereotypy and cataleptic freeze has been shown to reoccur for up to 21 days after the single dose administration. 6) PCP is thought to act as an indirect agonist of dopamine and alterations in the dopaminergic system are thought to be one of the underlying neurochemical substrates for PCP induced behaviour. 2, 8) Indeed, PCP treatment has been shown to increase levels of dopamine and its metabolites such as DOPAC and HVA, in the striatum, nucleus accumbens and medial prefrontal cortex in the rodent 7, 9, 12, 13) and primate brain. 12) In addition, PCP induced behaviours can be attenuated or blocked by a range of D1 and D2 dopamine receptor antagonists. 10, [14] [15] [16] Few studies however have examined short term changes that occur in dopamine receptor systems following PCP exposure particularly in the female rat brain 17) despite reported sexual dimorphism in some metabolic and behavioural responses to PCP treatment. [18] [19] [20] In the current study, we investigated whether rapid alterations occur in dopamine receptors shortly after PCP exposure, in female rats. We examined brain regions targeted by the mesolimbic dopamine pathway (ventral tegmental area to accumbens and olfactory tubercle) since dysregulation of dopamine in these regions is believed to lead to psychosis, particularly the positive symptoms of schizophrenia. 21) We also looked at brain regions that are targeted by the nigrostriatal pathway (substania nigra to striatum), which is important in the control of movement and locomotion that are affected by PCP. 6) In vitro autoradiography was carried out using [ C on a 12-12 h light-dark cycle and were allowed 1 week to acclimatise prior to the experiment. Food and water were freely available. The day of PCP treatment, rats were randomised and divided into one control group that received saline vehicle and one treated group that received PCP (40 mg/kg, i.p.). Both groups were decapitated under carbon dioxide anaesthesia 4 h post injection. Brains were removed and frozen in isopentane. Coronal brain sections (20μm) were cut with a cryostat and thaw mounted onto gelatinised microscope slides. Consecutive sections (six per slide) were taken from two brain compartments corresponding to plates 12-15 and 28-35 from a standard brain atlas. 22) In vitro Autoradiography Experiments were conducted using a single saturating 
Quantitative Analysis of Autoradiographic Images
All films were analyzed by using a computer-assisted image analysis system, Multi-Analyst, connected to a GS-690 Imaging Densitometer (Bio-Rad, USA). As detailed in Fig. 1 (Fig. 2) . Quantification of receptor binding in each brain region was performed by measuring the average optical density in six adjacent brain sections (three for the total binding and three for the non-specific binding). Non-specific binding was subtracted from the total binding to determine the specific binding. Optical density measurements for specific binding were then converted into fmoles [ (Fig. 1, 2 
RESULTS
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0001).
A significant interaction between treatment and region was not found. Post hoc tests did not detect any statistically significant individual changes in binding in brain region or treatment group (Fig. 1, 3) although the increase in the lateral caudate putamen approached significance (p=0.086). These results indicate that non-significant increases in [ 3 H] raclopride binding (medial caudate putamen=0.75%; lateral caudate putamen=10%; nucleus accumbens=13%; olfactory tubercle=15%) occurred in the regions assessed in PCP treated rats compared to controls, the sum of these changes resulting in the significant, region-wide effect of PCP treatment on [ 3 H] raclopride binding.
29)
DISCUSSION
The main findings of the current study are that acute treatment with PCP is associated with 18% decrease in D1R binding in the medial caudate putamen and a significant overall increase in D2R binding in the female rat brain, 4 hours after exposure.
Our results are in agreement with a previous study conducted in male rats in which D1R and D2R levels were examined in the 2 hour period after exposure to PCP.
17)
Tomić et al. 17) reported decreases following PCP treat-
] SCH 23390 binding of 25% and 33% in the striatum and nucleus accumbens. Using the D2R antagonist, [ 3 H] spiperone, they also reported an increase in D2R binding in the striatum. Despite sexual dimorphism reported for some of the metabolic 19) and behavioural effects of PCP 18, 19) it appears that the effects of acute PCP treatment on dopamine receptor binding density are similar in the male 17) and female rat brain (our study). The changes in dopamine receptor binding levels observed in the current study reflect opposing D1R and D2R adaptive responses to receptor stimulation.
3) PCP is thought to act as an indirect agonist of dopamine. 2, 8) D1Rs
are postsynaptically located where their activation generally leads to an excitatory neuronal response. 30, 31) The significant decrease in D1R levels observed in the medial caudate putamen accompanied by non-significant decreases in the lateral caudate putamen and accumbens following acute PCP treatment probably reflects an adaptive downregulation in response to a drug-induced increase in dopamine levels in these regions. 3, 7, 9, 12, 13) 
33)
D2Rs are not only postsynaptically located like D1Rs but they are also found on dopamine cell bodies where they act as autoreceptors regulating the firing rate of DA neurons. 31) As mentioned above, PCP increases levels of dopamine in the brain therefore the increase in D2R levels observed in the current study may reflect a compensatory upregulation of the D2 autoreceptor in order to counteract the dopaminergic hyperactivity induced by PCP treatment. 31) In contrast to our study however an in vivo PET imaging study in female baboons reported small decreases in [11C]raclopride binding in the striatum after a range of doses of PCP. 34) The discrepancies between our study and results reported in the literature for both D1R and D2R binding may reflect methodological differences, type and dose of antagonist used as well as species or gender differences. More detailed observations on the effects of NMDA receptor antagonism on brain dopamine receptors and how they are affected by dose, animal species or gender, are required to reach a consensus.
In the same cohort of animals used is this study, previously we have shown that acute exposure to PCP is associated with a marked decrease in AMPA receptor levels in cortical and limbic brain regions 35) suggesting that PCP produces a prominent disruption of glutamatergic function in these regions. It is possible that acute changes in AMPA and dopamine receptors levels after PCP treatment are related since it has been shown that AMPA receptor activity influences dopamine release in the nucleus accumbens.
36)
Interestingly, the adaptive responses induced by acute PCP exposure observed in the current study mirror some changes that are observed in dopamine receptor levels in schizophrenic patients. PET and SPECT studies for example have revealed that schizophrenic patients show a 10-20% elevation in the density of the D2R (one of the main targets for antipsychotic drugs) in the striatum compared to controls, independent of the effects of antipsychotics. 37) Alterations in D1R levels are also associated with cognitive impairments and negative symptoms in schizophrenia. 37) The results of imaging studies however are still inconclusive with reports of reduced, unchanged and elevated D1R levels from various studies.
37)
Our findings indicate that rapid changes occur in the dopaminergic system in the female rat brain following acute PCP exposure and may help to elucidate the underlying mechanisms by which a single PCP exposure causes psychotic symptoms in normal individuals. Based on our findings and those of Tomić et al., 17) the acute effects of PCP on D1R and D2R binding are similar in male and female rats.
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